hVIVO（CRO）株式概要hVIVO plcは英国、欧州、北米で医薬品サービスおよび開発業務受託会社として事業を展開している。 詳細CRO ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長4/6過去の実績0/6財務の健全性6/6配当金0/6報酬当社が推定した公正価値より37.3%で取引されている 収益は年間72.73%増加すると予測されています リスク分析German市場と比較して、過去 3 か月間の株価の変動が非常に大きい意味のある時価総額がありません ( €54M )すべてのリスクチェックを見るCRO Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW478,154 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA478,154 investors already sharing narrativesYour Fair Value€Current Price€0.06782.5% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-11m72m2016201920222025202620282031Revenue UK£71.9mEarnings UK£9.1mAdvancedSet Fair ValueView all narrativeshVIVO plc 競合他社PExASymbol: DB:FA0Market cap: €72.7mEvotecSymbol: XTRA:EVTMarket cap: €615.4mGerresheimerSymbol: XTRA:GXIMarket cap: €924.3mSCHOTT Pharma KGaASymbol: XTRA:1SXPMarket cap: €3.1b価格と性能株価の高値、安値、推移の概要hVIVO過去の株価現在の株価UK£0.06752週高値UK£0.1452週安値UK£0.044ベータ1.711ヶ月の変化-17.90%3ヶ月変化-30.00%1年変化-31.09%3年間の変化-60.42%5年間の変化-76.75%IPOからの変化9.02%最新ニュースお知らせ • Apr 17+ 1 more updatehVIVO plc, Annual General Meeting, May 13, 2026hVIVO plc, Annual General Meeting, May 13, 2026. Location: the offices of dac beachcroft llp, 25 walbrook, ec4n 8af, london United Kingdomお知らせ • Apr 07hVIVO plc to Report Fiscal Year 2025 Final Results on Apr 15, 2026hVIVO plc announced that they will report fiscal year 2025 final results at 8:00 AM, GMT Standard Time on Apr 15, 2026お知らせ • Nov 27hVIVO plc Announces Positive Results from Phase IIb TrialhVIVO plc congratulates its client Cidara Therapeutics Inc. which has entered into a definitive agreement under which Merck Sharp & Dohme LLC ("MSD"), through a subsidiary, will acquire Cidara for a total transaction value of approximately $9.2 billion. This transaction underscores the value of hVIVO's unique capabilities in accelerating drug development and validates the Company's strategic role in supporting breakthrough therapies. Cidara's lead candidate, CD388 is an investigational, long-acting, strain-agnostic antiviral agent designed to prevent influenza infection in individuals at higher risk of complications and offers protection against both influenza A and B. CD388 is currently in Phase III clinical development and has received Breakthrough Therapy Designation and Fast Track Designation from the U.S. FDA. hVIVO has partnered with Cidara throughout the development of CD388, delivering critical data that enabled its progression from early proof-of-concept to late-stage trials. Completed in 2023, hVIVO conducted a randomized, double-blind influenza human challenge study in healthy volunteers, providing early proof-of-concept data for CD388 ahead of later stage trials. 59 study participants were enrolled into the study and the primary efficacy analysis comparing the total viral load (area under the curve /AUC) showed a reduction in the CD388 treated arm compared to placebo. Similarly, the peak viral loads measured by both qPCR and cell culture were lowered in CD388 treated participants compared to placebo. This achievement demonstrated hVIVO's ability to execute large-scale field studies with speed and precision. The Phase IIb data read-out showed that all the primary and secondary endpoints were met. The Company continues to support Cidara through Phase III development, acting as a major clinical site for the ongoing multi-site trial. In addition, hVIVO has acted as the central Virology Laboratory for both of Cidara's CD388 Phase IIb and Phase III programs. As part of this service provision hVIVO has provided scientific consultancy, assembled sample collection kits, managed global virology sample logistics, and is responsible for multiple virology and immunology assays including the primary endpoint analysis.お知らせ • Nov 11hVIVO plc Presents Positive Data from Multiple Novel Human Challenge ModelshVIVO plc announced key insights from its scientific presentations at the 10th European Scientific Working Group on Influenza ("ESWI") Conference in Valencia, and the World Vaccine Congress Europe in Amsterdam, which both took place in October 2025. hVIVO presented positive data from a number of newly developed human challenge models, all demonstrating an acceptable safety and tolerability profile, reinforcing hVIVO's continued capabilities in accelerating the development of novel challenge agents and its readiness to meet customer demand for innovative and effective clinical trial solutions. Human Metapneumovirus ("hMPV") challenge model hVIVO's Senior Study Physician, Dr Alexander Lima, presented the positive findings from the newly developed, and world's only contemporary-strain hMPV human challenge model. The presentation at ESWI, titled, " Disease characteristics and immunological profiles obtained from newly developed hVIVO human challenge model", highlighted the model's strong performance using a recent 2a strain, which compared favourably against hVIVO's established RSV A model, a benchmark for model performance for this particular virus family. The model demonstrated high infection and symptomatic disease attack rates and robust AUC virology by qRT-PCR, and is now ready and available for vaccine and antiviral human challenge trials. SARS-CoV-2 Omicron challenge model Alex Mann, Senior Director Clinical Science presented, " Development of a SARS-CoV- 2 Omicron BA5 human challenge mode l" at ESWI. A key insight from the presentation was the importance of timing of dosing post-inoculation, particularly in the context of post-exposure prophylaxis. This represents the first commercially available Omicron human challenge model. Respiratory Syncytial Virus B (RSV B) challenge model At the World Vaccine Congress Europe, hVIVO's Chief Scientific Officer, Dr Andrew Catchpole showcased the positive results from hVIVO's new RSV B model titled, " High infection rates achieved with the world' first RSV B challenge models key component of the RSV-hMPV-PIV combination vaccine efficacy testing platform. The data confirmed the robustness of the RSV B model, which is now available for vaccine and anti-viral efficacy testing. The development of the RSV B and hMPV models, along with the Company's collecting of PIV (parainfluenza virus) clinical samples, has enabled the Company to create a comprehensive efficacy testing platform enabling the Company to test individual components of the next generation combination vaccines under development.お知らせ • Sep 04hVIVO plc to Report Q2, 2025 Results on Sep 23, 2025hVIVO plc announced that they will report Q2, 2025 results on Sep 23, 2025お知らせ • Sep 01Hvivo plc Appoints Shaun Chilton to Board of Directors as Non-Executive Chair with Effect from September 1, 2025hVIVO plc Shaun Chilton has joined the Board of Directors as Non-Executive Chair with immediate effect. Shaun brings substantial sector-relevant experience and expertise to the Board, underpinned by a track record of delivering strong growth in sales and enterprise value. He brings over 30 years of experience leading and managing both private and public businesses. Shaun was previously Chief Executive Officer of Clinigen Group plc, a global pharmaceutical services group operating in more than 100 countries and has considerable board experience within UK public companies. He is currently Non-Executive Chair of Avacta Group plc, Non-Executive Chair of Kintiga Limited, and Independent Supervisory Board Member of Product Life Group. The following additional information is provided with regards to the appointment of Shaun Edward Chilton, aged57, in accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies: Current directorships/partnerships: Avacta Group plc; Bellbrook Consulting Limited; Mustang Bidco Limited; Mustang Midco Limited; Mustang Topco Limited. Former directorships/partnerships (within the last five years): C7 Health Limited; Clinigen Clinical Trials Limited; Clinigen Consulting Limited; Clinigen CTS Limited; Clinigen Gap Limited; Clinigen Healthcare Limited; Clinigen Holdings Limited; Clinigen International Holdings Limited; Clinigen Limited; Clinigen Pharma Limited; Definigen Limited; IDIS GA Limited; IDIS Group Holdings Limited; IDIS Group LimitedIDIS Limited; IDIS MA Limited; IDIS Pharma Limited; Iovance Biotherapeutics UK SP Ltd; Keats Healthcare Limited.最新情報をもっと見るRecent updatesお知らせ • Apr 17+ 1 more updatehVIVO plc, Annual General Meeting, May 13, 2026hVIVO plc, Annual General Meeting, May 13, 2026. Location: the offices of dac beachcroft llp, 25 walbrook, ec4n 8af, london United Kingdomお知らせ • Apr 07hVIVO plc to Report Fiscal Year 2025 Final Results on Apr 15, 2026hVIVO plc announced that they will report fiscal year 2025 final results at 8:00 AM, GMT Standard Time on Apr 15, 2026お知らせ • Nov 27hVIVO plc Announces Positive Results from Phase IIb TrialhVIVO plc congratulates its client Cidara Therapeutics Inc. which has entered into a definitive agreement under which Merck Sharp & Dohme LLC ("MSD"), through a subsidiary, will acquire Cidara for a total transaction value of approximately $9.2 billion. This transaction underscores the value of hVIVO's unique capabilities in accelerating drug development and validates the Company's strategic role in supporting breakthrough therapies. Cidara's lead candidate, CD388 is an investigational, long-acting, strain-agnostic antiviral agent designed to prevent influenza infection in individuals at higher risk of complications and offers protection against both influenza A and B. CD388 is currently in Phase III clinical development and has received Breakthrough Therapy Designation and Fast Track Designation from the U.S. FDA. hVIVO has partnered with Cidara throughout the development of CD388, delivering critical data that enabled its progression from early proof-of-concept to late-stage trials. Completed in 2023, hVIVO conducted a randomized, double-blind influenza human challenge study in healthy volunteers, providing early proof-of-concept data for CD388 ahead of later stage trials. 59 study participants were enrolled into the study and the primary efficacy analysis comparing the total viral load (area under the curve /AUC) showed a reduction in the CD388 treated arm compared to placebo. Similarly, the peak viral loads measured by both qPCR and cell culture were lowered in CD388 treated participants compared to placebo. This achievement demonstrated hVIVO's ability to execute large-scale field studies with speed and precision. The Phase IIb data read-out showed that all the primary and secondary endpoints were met. The Company continues to support Cidara through Phase III development, acting as a major clinical site for the ongoing multi-site trial. In addition, hVIVO has acted as the central Virology Laboratory for both of Cidara's CD388 Phase IIb and Phase III programs. As part of this service provision hVIVO has provided scientific consultancy, assembled sample collection kits, managed global virology sample logistics, and is responsible for multiple virology and immunology assays including the primary endpoint analysis.お知らせ • Nov 11hVIVO plc Presents Positive Data from Multiple Novel Human Challenge ModelshVIVO plc announced key insights from its scientific presentations at the 10th European Scientific Working Group on Influenza ("ESWI") Conference in Valencia, and the World Vaccine Congress Europe in Amsterdam, which both took place in October 2025. hVIVO presented positive data from a number of newly developed human challenge models, all demonstrating an acceptable safety and tolerability profile, reinforcing hVIVO's continued capabilities in accelerating the development of novel challenge agents and its readiness to meet customer demand for innovative and effective clinical trial solutions. Human Metapneumovirus ("hMPV") challenge model hVIVO's Senior Study Physician, Dr Alexander Lima, presented the positive findings from the newly developed, and world's only contemporary-strain hMPV human challenge model. The presentation at ESWI, titled, " Disease characteristics and immunological profiles obtained from newly developed hVIVO human challenge model", highlighted the model's strong performance using a recent 2a strain, which compared favourably against hVIVO's established RSV A model, a benchmark for model performance for this particular virus family. The model demonstrated high infection and symptomatic disease attack rates and robust AUC virology by qRT-PCR, and is now ready and available for vaccine and antiviral human challenge trials. SARS-CoV-2 Omicron challenge model Alex Mann, Senior Director Clinical Science presented, " Development of a SARS-CoV- 2 Omicron BA5 human challenge mode l" at ESWI. A key insight from the presentation was the importance of timing of dosing post-inoculation, particularly in the context of post-exposure prophylaxis. This represents the first commercially available Omicron human challenge model. Respiratory Syncytial Virus B (RSV B) challenge model At the World Vaccine Congress Europe, hVIVO's Chief Scientific Officer, Dr Andrew Catchpole showcased the positive results from hVIVO's new RSV B model titled, " High infection rates achieved with the world' first RSV B challenge models key component of the RSV-hMPV-PIV combination vaccine efficacy testing platform. The data confirmed the robustness of the RSV B model, which is now available for vaccine and anti-viral efficacy testing. The development of the RSV B and hMPV models, along with the Company's collecting of PIV (parainfluenza virus) clinical samples, has enabled the Company to create a comprehensive efficacy testing platform enabling the Company to test individual components of the next generation combination vaccines under development.お知らせ • Sep 04hVIVO plc to Report Q2, 2025 Results on Sep 23, 2025hVIVO plc announced that they will report Q2, 2025 results on Sep 23, 2025お知らせ • Sep 01Hvivo plc Appoints Shaun Chilton to Board of Directors as Non-Executive Chair with Effect from September 1, 2025hVIVO plc Shaun Chilton has joined the Board of Directors as Non-Executive Chair with immediate effect. Shaun brings substantial sector-relevant experience and expertise to the Board, underpinned by a track record of delivering strong growth in sales and enterprise value. He brings over 30 years of experience leading and managing both private and public businesses. Shaun was previously Chief Executive Officer of Clinigen Group plc, a global pharmaceutical services group operating in more than 100 countries and has considerable board experience within UK public companies. He is currently Non-Executive Chair of Avacta Group plc, Non-Executive Chair of Kintiga Limited, and Independent Supervisory Board Member of Product Life Group. The following additional information is provided with regards to the appointment of Shaun Edward Chilton, aged57, in accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies: Current directorships/partnerships: Avacta Group plc; Bellbrook Consulting Limited; Mustang Bidco Limited; Mustang Midco Limited; Mustang Topco Limited. Former directorships/partnerships (within the last five years): C7 Health Limited; Clinigen Clinical Trials Limited; Clinigen Consulting Limited; Clinigen CTS Limited; Clinigen Gap Limited; Clinigen Healthcare Limited; Clinigen Holdings Limited; Clinigen International Holdings Limited; Clinigen Limited; Clinigen Pharma Limited; Definigen Limited; IDIS GA Limited; IDIS Group Holdings Limited; IDIS Group LimitedIDIS Limited; IDIS MA Limited; IDIS Pharma Limited; Iovance Biotherapeutics UK SP Ltd; Keats Healthcare Limited.お知らせ • Jul 18hVIVO plc Announces Resignation of Tracey James as Non-Executive Director, Effective 18 July 2025hVIVO plc announced that the Company has received notice of resignation from Tracey James as Non-Executive Director of the Board with immediate effect (18 July 2025). The Company confirmed that Ms. James' decision to resign from the Board is unrelated to the Company's financial performance or outlook. The Nominations Committee has commenced a process to appoint a new independent Non-Executive Director, and the Company will announce the results of this process in due course. Separately, the Nominations Committee is progressing well in its process to appoint a new independent Non-Executive Chair, with a further announcement to be made in due course.お知らせ • May 13hVIVO plc, Annual General Meeting, Jun 05, 2025hVIVO plc, Annual General Meeting, Jun 05, 2025. Location: the offices of cavendish capital markets ltd, 1 bartholomew close, ec1a 7bl, london United Kingdomお知らせ • Apr 10+ 1 more updatehVIVO plc Proposes Ordinary Dividend for the Year Ended 31 December 2024, Payable 11 June 2025hVIVO plc announced A final dividend for the year ended 31 December 2024 of £1,374,000 (0.20p per ordinary share) is recommended by the Directors and is to be paid to all ordinary shareholders on the register at the close of business on 16 May 2025 with payment being made on 11 June 2025, subject to shareholder approval at the Annual General Meeting. The corresponding ex-dividend date is 15 May 2025.お知らせ • Mar 21hVIVO plc to Report Fiscal Year 2024 Results on Apr 10, 2025hVIVO plc announced that they will report fiscal year 2024 results at 11:00 AM, GMT Standard Time on Apr 10, 2025お知らせ • Feb 27hVIVO plc (AIM:HVO) acquired Cryo Store Limited.hVIVO plc (AIM:HVO) acquired Cryo Store Limited on February 27, 2025. Under the terms of the Acquisition, three managers of Cryostore will be issued up to 2,773,982 ordinary shares of £1p each in hVIVO ('Consideration Shares') with an aggregate value of up to £0.5 million at the average closing share price for the ten days prior to 24 February 2024. 1,386,991of the Consideration Shares (being 50%) will be allotted on the 12-month anniversary of completion with1,386,991 of the Consideration Shares (being 50%) being allotted on the second anniversary of the Acquisition, subject to the individuals remaining in service of the Group at the time of the allotments. For the period ending December 31, 2024, Cryo Store Limited reported total revenue of £0.89 million and EBITDA of £0.52 million. As of December 31, 2024, Cryo Store Limited reported total common equity of £0.84 million. Geoff Nash, Camilla Hume, Harriet Ward, Nigel Birks, Louise Talbot of Cavendish Capital Markets Limited acted as financial advisor for hVIVO plc. hVIVO plc (AIM:HVO) completed the acquisition of Cryo Store Limited on February 27, 2025.お知らせ • Jan 31hVIVO plc (AIM:HVO) acquired Two Clinical Research Units of Crs Clinical Research Services Management GmbH for €10 million.hVIVO plc (AIM:HVO) acquired Two Clinical Research Units of Crs Clinical Research Services Management GmbH for €10 million on January 29, 2025. Under the terms of agreement, the Acquisition has been completed for a cash consideration of €10.0 million, wholly funded from the Group's existing cash resources. For the period ending December 31, 2024, The Mannheim and Kiel units recorded unaudited revenues of €19.9 million, with an adjusted EBITDA loss of €1.8 million. Under hVIVO's ownership the two units will undergo an investment and restructuring programme to assist with their integration which is expected to cost c.€2.5 million in 2025 including net liabilities being acquired of less than €0.5 million. Following the Acquisition, average contract sizes across the Group are anticipated to increase, as well as growth in the CRS sales pipeline. The current senior leadership team at CRS, consisting of Dr. Elisabeth Lackner, Chief Executive Officer; Catherine Canales, Chief Commercial Officer; Prof. Dr. Thomas Forst, Chief Medical Officer; and Till Mieskes, Chief Financial Officer, will continue in their roles. The Acquisition expected to be earnings accretive in 2026. The integration of the Acquisition into the wider Group is expected to impact EBITDA margins in the short term and the Group expects to deliver strong revenue growth in 2026 and a significant improvement on EBITDA margins following the integration of CRS. Geoff Nash and Camilla Hume of Cavendish Capital Markets Limited acted as financial advisor for hVIVO plc. hVIVO plc (AIM:HVO) completed the acquisition of Two Clinical Research Units of Crs Clinical Research Services Management GmbH on January 29, 2025.お知らせ • Aug 20hVIVO plc to Report First Half, 2024 Results on Sep 10, 2024hVIVO plc announced that they will report first half, 2024 results on Sep 10, 2024お知らせ • Aug 05hVIVO Proposes Cancellation of Admission to Trading on Euronext GrowthhVIVO plc announced its intention to cancel its admission ("the Cancellation") to trading on Euronext Growth. As hVIVO's primary operations, along with the majority of its employees and investor base, are in the UK,the Board has decided to consolidate trading of the Company's stock to its primary listing on the AIM Market of the London Stock Exchange. The Cancellation will also remove certain costs, complexities and duplication that comes from administering two listing regimes and will have no impact on hVIVO's Ordinary Shares which will continue to trade on AIM under the ticker "HVO". In accordance with the Euronext Growth Rules, the Company has notified Euronext of the proposed Cancellation. Under the Euronext Growth Rules, the Cancellation can only take place after the expiry of a minimum period of twenty Business Days from the date on which notice of the Cancellation is given. Accordingly, it is intended that the Cancellation will become effective at 7.00 a.m. on 2 September 2024.お知らせ • Apr 16hVIVO plc, Annual General Meeting, May 13, 2024hVIVO plc, Annual General Meeting, May 13, 2024, at 10:00 Coordinated Universal Time.New Risk • Apr 09New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 17% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings are forecast to decline by an average of 17% per year for the foreseeable future.Reported Earnings • Apr 09Full year 2023 earnings released: EPS: UK£0.024 (vs UK£0.001 loss in FY 2022)Full year 2023 results: EPS: UK£0.024 (up from UK£0.001 loss in FY 2022). Revenue: UK£58.7m (up 16% from FY 2022). Net income: UK£16.1m (up UK£16.9m from FY 2022). Profit margin: 28% (up from net loss in FY 2022). The move to profitability was primarily driven by lower expenses. Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 142% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.お知らせ • Mar 27hVIVO plc to Report Fiscal Year 2023 Results on Apr 09, 2024hVIVO plc announced that they will report fiscal year 2023 results on Apr 09, 2024お知らせ • Feb 15hVIVO plc has completed a Follow-on Equity Offering in the amount of £8.38745 million.hVIVO plc has completed a Follow-on Equity Offering in the amount of £8.38745 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 29,955,178 Price\Range: £0.28 Transaction Features: Subsequent Direct ListingBuying Opportunity • Jan 05Now 22% undervaluedOver the last 90 days, the stock is up 32%. The fair value is estimated to be €0.37, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 39% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 6.5% per annum. Earnings is also forecast to grow by 17% per annum over the same time period.お知らせ • Jan 02hVIVO plc Signs £6.3 Million Human Challenge Study ModelhVIVO plc announced that it has signed a £6.3m contract with a biotechnology client to test its antiviral candidate using the hVIVO Human Rhinovirus (HRV - common cold virus) Human Challenge Study Model. The Phase 2a randomised, double-blinded placebo-controlled human challenge trial is planned to take place at the Company's new specialist quarantine facilities in Canary Wharf. It will evaluate the effect of the antiviral candidate on viral load, safety, tolerability, and prophylactic antiviral activity against HRV infection in multiple cohorts of healthy volunteers. The study is expected to commence in H2 2024, with revenue recognised in 2024 and 2025. As part of the study, hVIVO will recruit healthy volunteers via the Company's dedicated volunteer recruitment arm, FluCamp. This biotechnology client recognises the benefit of human challenge in quickly generating early human efficacy data, which has the potential of significantly enhancing the value of their clinical asset. Human rhinoviruses (HRV) are a group of pathogens that cause 'the common cold', with over 150 distinct types of HRV currently known. Although one third of HRV infections are asymptomatic, it can be potentially serious in the elderly, immunocompromised and those with existing respiratory diseases, and there is strong evidence of a relationship between HRV infection and more severe symptoms of asthma and COPD. To date, no antiviral has been approved in the prevention or treatment of HRV infection.お知らせ • Sep 12hVIVO plc Increases Revenue Guidance for 2023The Board of hVIVO plc has increased its revenue guidance to £55 million for 2023.お知らせ • Aug 24hVIVO plc to Report First Half, 2023 Results on Sep 12, 2023hVIVO plc announced that they will report first half, 2023 results on Sep 12, 2023お知らせ • Jun 30hVIVO plc to Develop Human Metapneumovirus Challenge ModelhVIVO plc is developing a human metapneumovirus (hMPV) challenge model. hVIVO has signed an agreement with a North American biopharmaceutical company to manufacture a hMPV virus and conduct a characterisation study, with the intent to conduct a subsequent hMPV challenge trial in 2024 to test the efficacy of its vaccine candidate. hVIVO will commence Good Manufacturing Practice (GMP) compliant virus manufacturing activities immediately and this is expected to complete in first half 2024. The Company will then conduct a characterisation study to identify a safe and infectious dose of wild-type hMPV in up to 36 healthy adult volunteers. Dependent on the successful completion of the characterisation study and receipt of relevant regulatory approvals, the Company expects to conduct hMPV challenge trials from second half of 2024. The majority of the revenue from this end-to-end human challenge service will be recognised in 2024. The client intends to utilise the efficacy data from the challenge study to define the endpoints for its hMPV vaccine candidate's clinical development programme, as well as providing a greater understanding of virus progression, aiding dosing decisions and confirming previous animal study results. This will allow the client to streamline future trials and make critical go/no-go decisions more quickly, therefore accelerating the development of the vaccine candidate. hMPV is a common virus that causes an upper respiratory infection, similar to the common cold. Symptoms include cough, fever, nasal congestion, and shortness of breath. Most people have mild cases of hMPV, but severe cases can result in bronchiolitis, bronchitis and pneumonia. hMPV is associated with approximately 20% of respiratory tract infections in children worldwide. Up to 16% of the children infected with hMPV develop more severe symptoms2, with over 16,000 deaths worldwide in children under the age of five each year. Despite its prevalence and potential severity, there are currently no vaccines or antivirals approved to treat hMPV.Reported Earnings • Apr 30Full year 2022 earnings released: UK£0.001 loss per share (vs UK£0 in FY 2021)Full year 2022 results: UK£0.001 loss per share (further deteriorated from UK£0 in FY 2021). Revenue: UK£50.7m (up 30% from FY 2021). Net loss: UK£776.0k (loss widened UK£702.0k from FY 2021). Revenue is forecast to grow 8.3% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 103% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth.Breakeven Date Change • Apr 27Forecast to breakeven in 2023The 3 analysts covering hVIVO expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of UK£5.19m in 2023. Average annual earnings growth of 53% is required to achieve expected profit on schedule.お知らせ • Jan 25hVIVO plc Provides Earnings Guidance for the Full Year 2022hVIVO plc provided earnings guidance for the full year 2022. The group expected to report record full year revenues of £50.6 million (2021: £39 million), a 30% increase year-on-year. The significant growth in revenue provides further validation of the long-term sustainable growth in the human challenge trial market, for which hVIVO is the world leader.Breakeven Date Change • Dec 31Forecast breakeven date pushed back to 2023The 3 analysts covering hVIVO previously expected the company to break even in 2022. New consensus forecast suggests the company will make a profit of UK£4.59m in 2023. Average annual earnings growth of 57% is required to achieve expected profit on schedule.お知らせ • Dec 20hVIVO plc Announces Publication of Imutex Phase I DatahVIVO plc announces publication of previously reported positive data from a first-in-human Phase I clinical study evaluating the safety and immunogenicity of AGS-v PLUS. The data has been published in eBioMedicine,1 a peer-reviewed open access biomedical journal part of The Lancet Discovery Science. AGS-v PLUS is a vaccine candidate against arboviral diseases that targets the saliva of the mosquito rather than the pathogens carried by the mosquito. AGS-v PLUS is owned by Imutex Ltd, a joint venture with PepTcell Limited (the parent company of ConserV Bioscience Ltd), in which hVIVO has a 49% shareholding. AGS-v PLUS vaccine candidate has a novel proposed dual action mechanism of preventing infection in humans whilst controlling the mosquito population through affecting reproduction. AGS-v PLUS contains five synthetic peptides that originate from proteins found in the saliva of mosquitoes. The published manuscript shows data from the study conducted at the University of Maryland School of Medicine and sponsored by NIAID-NIH, demonstrating that all AGS-v PLUS formulations evaluated (non-adjuvanted or adjuvanted in alhydrogel or Montanide ISA-51) were well tolerated with no serious adverse events experienced, and that they generated a robust cellular and humoral immune response in participants, the formulation in Montanide ISA-51 being the most immunogenic. Moreover, the immune response mounted against AGS-v PLUS was shown to reduce infectivity of Zika virus in vitro. Mosquito-borne diseases include Zika, West Nile, chikungunya, dengue, yellow fever, and malaria amongst others. There are ~360 million cases of and more than 600,000 deaths from mosquito-borne diseases annually, although the true burden is likely underestimated. A vaccine efficacious against multiple mosquito-borne diseases could significantly impact public health.Buying Opportunity • Dec 20Now 20% undervaluedOver the last 90 days, the stock is up 29%. The fair value is estimated to be €0.15, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 66% over the last 3 years. Earnings per share has grown by 97%.Board Change • Nov 16Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (4 non-independent directors). Non-Executive Chairman Cathal Friel is the most experienced director on the board, commencing their role in 2020. Independent Non-Executive Director Martin Gouldstone was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Oct 18+ 1 more updateOpen Orphan plc Announces Chief Financial Officer ChangesOpen Orphan plc announced the appointment of Stephen Pinkerton as Chief Financial Officer and as an Executive Director, effective with immediate effect. Stephen will succeed Leo Toole who steps down from the Board and CFO role to pursue other interests. Leo will remain with the Company until 31 December 2022. Stephen is a chartered accountant with over 25 years of experience in senior financial roles and has served as Commercial Financial Director of hVIVO since July 2017, having previously been a consultant to the Company. Prior to joining hVIVO, Stephen spent 11 years in various senior financial roles at Thomson Reuters. He will be based in the Company's Plumbers Row headquarters in East London alongside the Company's CEO Yamin 'Mo' Khan. Stephen has a strong background in financial planning and analysis, commercial finance, financial systems and financial control. As Commercial Financial Director of hVIVO, he has worked to transform the reporting and forecasting of the business, developed pricing models for contracts to help improve average contract value as well as driving margin improvements across the business, and has served as part of the business development team negotiating contract terms. As part of the leadership team, he has worked to help manage costs and restructure the business to improve efficiency, resulting in continued improvements in profitability.お知らせ • Oct 01Open Orphan plc Announces Positive Data from Peer-Reviewed Study Evaluating the in Vitro Efficacy of Flu-VOpen Orphan plc announced that positive data from a peer-reviewed study evaluating the in vitro efficacy of FLU-v, Imutex Limited's ("Imutex") broad spectrum influenza vaccine, has been published in the scientific journal Vaccines. Previous clinical studies have demonstrated that FLU-v induced increased antibody and cellular responses in vivo. This placebo-controlled study evaluated the ability of FLU-v to induce cellular effector functions and cross-reactivity (both measures of the immune response, with cross-reactivity being particularly important for protection against multiple viral strains) of immune cells extracted from participants, following exposure to five different influenza strains.The study found that measurements ofIFN-? and granzyme B production in stimulated immune cells from participants that had been previously vaccinated with either FLU-v or placebo, were significantly higher in the FLU-v group both when stimulated with vaccine antigen and also with antigens from a panel of seasonal and pandemic inactivated influenza A and B strains. These results further support the continued development of FLU-v as a broad-spectrum influenza vaccine. FLU-v is owned by Imutex, a joint venture between hVIVO andPepTcell Limited (the legal name of SEEK Group), to develop vaccines against influenza and mosquito borne diseases such as Zika virus, malaria and other flaviviruses.Reported Earnings • Sep 09First half 2022 earnings released: EPS: UK£0 (vs UK£0.002 in 1H 2021)First half 2022 results: EPS: UK£0 (down from UK£0.002 in 1H 2021). Revenue: UK£18.9m (down 14% from 1H 2021). Net income: UK£277.0k (down 78% from 1H 2021). Profit margin: 1.5% (down from 5.8% in 1H 2021). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.お知らせ • Sep 08Open Orphan plc Reiterates Revenue Guidance for the Full Year of 2022Open Orphan Plc reiterated revenue guidance for the full year of 2022. For the year, the company reiterated revenue guidance of c. £50 million, underpinned by robust trading in July and August and record contracted order book increased nearly threefold to c. £70 million as at 30 June 2022.お知らせ • Aug 25Open Orphan Plc to Report First Half, 2022 Results on Sep 08, 2022Open Orphan Plc announced that they will report first half, 2022 results on Sep 08, 2022お知らせ • Jun 11Open Orphan plc, Annual General Meeting, Jul 05, 2022Open Orphan plc, Annual General Meeting, Jul 05, 2022, at 10:00 Coordinated Universal Time. Location: at the offices of DAC Beachcroft LLP, 25 Walbrook London United KingdomReported Earnings • Jun 08Full year 2021 earnings released: EPS: UK£0 (vs UK£0.018 loss in FY 2020)Full year 2021 results: EPS: UK£0 (up from UK£0.018 loss in FY 2020). Revenue: UK£39.0m (up 89% from FY 2020). Net loss: UK£74.0k (loss narrowed 99% from FY 2020). Over the next year, revenue is forecast to grow 7.0%, compared to a 13% growth forecast for the pharmaceuticals industry in Germany.お知らせ • Jun 08Open Orphan plc Appoints Martin Gouldstone as Independent Non-Executive DirectorOpen Orphan plc announced the appointment of Martin Gouldstone as an Independent Non-Executive Director of the Company with effect from 8 June 2022.Martin will also Chair the Audit & Risk Committee and will be a member of the Nominations Committee and the Remuneration Committee. Martin brings 30 years of corporate development experience in the CRO, healthcare and pharmaceutical sectors, holding a number of senior roles at healthcare AI businesses. Martin has expertise in executing multi-billion dollar deals across Europe and the US, architecting end-to-end portfolio out-sourcing deals, and negotiating multi-year research partnerships. Martin is currently Global SVP, Business Development at Owkin. Previously, Martin has held the roles of Chief Business Officer at both BenevolentAI and Sensyne Health and was a Partner at Results Healthcare. Prior to this, Martin was Head of Life Sciences for BDO UK LLP, Senior Director responsible for M&A and joint venture opportunities in Europe for Quintiles (now IQVIA), and Business Development and Licensing Lead at Confirmant Ltd, Pharmacopeia Inc, Sareum Ltd. Martin holds a BSc in Genetics and has completed a range of post graduate management courses.お知らせ • May 24Open Orphan plc to Report Fiscal Year 2021 Results on Jun 07, 2022Open Orphan plc announced that they will report fiscal year 2021 results on Jun 07, 2022Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 1 independent director (4 non-independent directors). Executive Chairman Cathal Friel is the most experienced director on the board, commencing their role in 2020. Independent Non-Executive Director Elaine Sullivan was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Apr 01Open Orphan plc Announces Characterisation Study Results in Nature MedicineOpen Orphan plc announced that the results from the world's first COVID-19 characterisation study have been peer reviewed and published in the scientific journal Nature Medicine. The study, which was conducted by hVIVO, a subsidiary of Open Orphan, in partnership with Imperial College London, the Vaccine Taskforce and Department of Health and Social Care (DHSC), and the Royal Free London NHS Foundation Trust, showed that the SARS-CoV-2 human challenge was safe in healthy young adults and provided detailed insights into the course of COVID-19 infection with potential positive public health implications. The study results had previously been published on Research Square whilst the peer review process was concluding. As part of the characterisation study, researchers aimed to identify a dose of COVID-19 that caused a safe and reliable infection in unvaccinated volunteers with no prior SARS-CoV-2 infection. hVIVO clinicians closely monitored volunteers in a controlled quarantined setting and collected disease progression data to provide insights into COVID-19 infection. With the characterisation study disease modelling data completed, and a COVID-19 Human Challenge Model now established, Open Orphan should be able to contract /conduct COVID-19 human challenge studies in 2022, subject to individual ethics and regulatory approvals.お知らせ • Feb 24Open Orphan plc Appoints Yamin 'Mo' Khan as Chief Executive OfficerOpen Orphan plc announces the appointment of Yamin 'Mo' Khan as Chief Executive Officer of Open Orphan with immediate effect. He previously worked at Pharm-Olam International, a global CRO, for 19 years from 2000-2019.Reported Earnings • Sep 22First half 2021 earnings released: EPS UK£0.002 (vs UK£0.012 loss in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: UK£21.9m (up 242% from 1H 2020). Net income: UK£1.27m (up UK£7.76m from 1H 2020). Profit margin: 5.8% (up from net loss in 1H 2020). The move to profitability was driven by higher revenue.Recent Insider Transactions • Jul 16Executive Chairman recently bought €352k worth of stockOn the 14th of July, Cathal Friel bought around 1m shares on-market at roughly €0.31 per share. This was the largest purchase by an insider in the last 3 months. This was Cathal's only on-market trade for the last 12 months.Reported Earnings • Jun 20Full year 2020 earnings released: UK£0.018 loss per share (vs UK£0.034 loss in FY 2019)The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2020 results: Revenue: UK£20.6m (up UK£17.3m from FY 2019). Net loss: UK£10.8m (loss widened 95% from FY 2019).Is New 90 Day High Low • Feb 23New 90-day high: €0.35The company is up 34% from its price of €0.26 on 24 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.083 per share.お知らせ • Feb 18Open Orphan plc Announces Ethics Approval for Covid-19 Human Challenge StudyOpen Orphan plc announced the COVID-19 characterisation study has received approval from a specially convened Research Ethics Committee ("REC"). The initial virus characterisation study will inoculate up to 90 volunteers, between the ages of 18 and 30 years old, to enable identification of the most appropriate dose of the virus needed to cause COVID-19 (SARS-CoV-2) infection in a safe and controlled environment. The study is set to commence shortly and is funded by the UK Government. Imperial College London is the clinical study sponsor and the study will be conducted by hVIVO at the Royal Free London NHS Foundation Trust's specialist clinical research unit, under the scrutiny of highly trained scientists and medics. The virus being used in the characterisation study has been produced under hVIVO's supervision by a team at Great Ormond Street Hospital for Children NHS Foundation Trust in London, with support from virologists at Imperial College London. The REC approval completes all the independent external body approvals required before the study can commence.お知らせ • Feb 02Open Orphan Plc's Subsidiary Venn Life Sciences Announces Contract Extension with Carna BiosciencesOpen Orphan plc announced a further contract renewal with Carna Biosciences Inc., extending its integrated drug development consultancy services with Venn Life Sciences, part of Open Orphan plc. The Venn team in the Breda office in the Netherlands, will provide Chemistry, Manufacturing & Control (CMC), Non-Clinical, Clinical and Regulatory consultancy services to this client for two of the client's leading development programmes. This successful collaboration has been extended until the end of December 2021.Is New 90 Day High Low • Jan 27New 90-day high: €0.33The company is up 44% from its price of €0.23 on 29 October 2020. The German market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.099 per share.お知らせ • Jan 07Open Orphan plc Announces Contract Renewal with Top-3 Pharmaceutical Client Extending Its Consultancy Services to End of December 2021Open Orphan plc announced a further contract renewal with a major top-3 global pharmaceutical client extending its consultancy services to end of December 2021. This follows on from the announcement made on 22 December 2020 regarding the same client and demonstrates the repeat business that Venn Life Sciences continues to win from its long-term clients. The Venn team in the Breda office in the Netherlands, will provide Chemistry, Manufacturing & Control consultancy services to this leading global pharmaceutical client for one of the client's vaccine development programmes and follows the recently announced contract renewal for work on two of the client's vaccine development programmes. This successful collaboration has been extended until end of December 2021.お知らせ • Nov 25Open Orphan plc Announces Board Changes, Effective on December 31, 2020Open Orphan plc announced the appointment of Elaine Sullivan as a Non-Executive Director to the board of the company. Elaine is a business leader and senior scientist with international experience in the pharmaceutical industry and Biotech and is the CEO of Curadh Pharmaceuticals. She has been a member of the most senior R&D management teams in Lilly and AstraZeneca. Elaine is a Non-Executive Director at IP Group plc and Active Biotech AB and is a member of the Supervisory Board at Evotec. The company also announced that Mark Warne, Non-Executive Director, will be stepping down from the board of the company on the of December 31.お知らせ • Nov 06Open Orphan plc Announces the Signs of A £2.5 Million Contract by hVIVOOpen Orphan plc announced the signing of a £2.5 million contract by hVIVO, a subsidiary of Open Orphan, to conduct an Influenza human challenge study with a US biotechnology company. The study is expected to commence at hVIVO's 24-bedroom quarantine clinic in East London in H2 2021 and to be fully completed by year end 2021, generating £2.5m of revenue. This contract builds on the Company's recent challenge study contract wins in RSV and COVID-19 and demonstrates the breadth of Open Orphan's service offering and the expertise within the Group as a world leader in its field. For this study, Venn Life Science's Paris team will complete the biometrics, demonstrating how the various parts of the Open Orphan plc Group can work together to deliver high-quality services to clients. Venn's Paris team are highly regarded in the field as one of the leading providers in this area which is a perfect complement to the London offering.Is New 90 Day High Low • Oct 05New 90-day high: €0.21The company is up 87% from its price of €0.11 on 07 July 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 18% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.29 per share.Is New 90 Day High Low • Oct 01New 90-day high: €0.20The company is up 66% from its price of €0.12 on 03 July 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 19% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.32 per share.お知らせ • Oct 01Open Orphan plc Announces £4.3 Million Contract to Conduct Human Viral Challenge StudyOpen Orphan plc announced £4.3 million contract to conduct human viral challenge study utilizing one of 8 traditional challenge study models for another of the global top 10 vaccine companies. This trial will be conducted in the company's dedicated human viral challenge quarantine unit in London with all volunteers recruited through hVIVO's volunteer recruitment website, www.flucamp.com. The hVIVO unit is Europe's only commercial 24-bedroom quarantine clinic with on-site virology laboratory. Work on this major new contract has started already and the contract is expected to be delivered in first quarter of 2021 with the majority of revenues being generated in first half of 2021. It is a further example of Open Orphan delivering on its pipeline and stated strategy of winning sizeable contracts.お知らせ • Sep 28Open Orphan plc to Report First Half, 2020 Results on Sep 30, 2020Open Orphan plc announced that they will report first half, 2020 results on Sep 30, 2020株主還元CRODE Life SciencesDE 市場7D-5.0%-8.4%0.1%1Y-31.1%0.1%-0.5%株主還元を見る業界別リターン: CRO過去 1 年間で0.1 % の収益を上げたGerman Life Sciences業界を下回りました。リターン対市場: CROは、過去 1 年間で-0.5 % のリターンを上げたGerman市場を下回りました。価格変動Is CRO's price volatile compared to industry and market?CRO volatilityCRO Average Weekly Movement19.3%Life Sciences Industry Average Movement6.4%Market Average Movement5.3%10% most volatile stocks in DE Market12.7%10% least volatile stocks in DE Market2.7%安定した株価: CROの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: CROの 週次ボラティリティ は過去 1 年間で28%から19%に減少しましたが、依然としてGerman株の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/a376Mo Khanwww.hvivo.comhVIVO plcは、英国、欧州、北米で医薬品サービスおよび開発業務受託会社として事業を展開している。同社は、ヒトチャレンジ臨床試験を用いたワクチンや抗ウイルスのテストに携わり、アッセイ開発、細胞ベースアッセイ、分子学、免疫学、ウイルス学、臨床フィールドトレイルロジスティクス、バイオマーカー分析サービスなどのラボサービスを提供している。RSV、インフルエンザ、COVID-19、hMPV、HRV、喘息、マラリア、COPDなどの疾患に対するヒトチャレンジ試験モデルのポートフォリオを有している。加えて、同社はウイルス学と免疫学に特化した研究所を提供しており、前臨床および臨床の呼吸器疾患治療薬、ワクチンの発見と開発をサポートする一連のサービスを提供している。さらに、前臨床および初期臨床研究サービス、営業・マーケティングサービス、データ管理、統計サービス、医薬品開発コンサルタント・サービスも提供している。同社は大手製薬会社やバイオテクノロジー企業にサービスを提供している。hVIVO plcの本社は英国ロンドンにある。もっと見るhVIVO plc 基礎のまとめhVIVO の収益と売上を時価総額と比較するとどうか。CRO 基礎統計学時価総額€54.35m収益（TTM）-€7.02m売上高(TTM)€58.21m0.9xP/Sレシオ-7.7xPER（株価収益率CRO は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計CRO 損益計算書（TTM）収益UK£49.66m売上原価UK£48.24m売上総利益UK£1.42mその他の費用UK£7.41m収益-UK£5.99m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.0087グロス・マージン2.86%純利益率-12.07%有利子負債／自己資本比率0%CRO の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/22 07:42終値2026/07/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋hVIVO plc 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11 アナリスト機関Michael MitchellCavendishAdam McCarterCavendishEdward ThomasonCGS International8 その他のアナリストを表示
お知らせ • Apr 17+ 1 more updatehVIVO plc, Annual General Meeting, May 13, 2026hVIVO plc, Annual General Meeting, May 13, 2026. Location: the offices of dac beachcroft llp, 25 walbrook, ec4n 8af, london United Kingdom
お知らせ • Apr 07hVIVO plc to Report Fiscal Year 2025 Final Results on Apr 15, 2026hVIVO plc announced that they will report fiscal year 2025 final results at 8:00 AM, GMT Standard Time on Apr 15, 2026
お知らせ • Nov 27hVIVO plc Announces Positive Results from Phase IIb TrialhVIVO plc congratulates its client Cidara Therapeutics Inc. which has entered into a definitive agreement under which Merck Sharp & Dohme LLC ("MSD"), through a subsidiary, will acquire Cidara for a total transaction value of approximately $9.2 billion. This transaction underscores the value of hVIVO's unique capabilities in accelerating drug development and validates the Company's strategic role in supporting breakthrough therapies. Cidara's lead candidate, CD388 is an investigational, long-acting, strain-agnostic antiviral agent designed to prevent influenza infection in individuals at higher risk of complications and offers protection against both influenza A and B. CD388 is currently in Phase III clinical development and has received Breakthrough Therapy Designation and Fast Track Designation from the U.S. FDA. hVIVO has partnered with Cidara throughout the development of CD388, delivering critical data that enabled its progression from early proof-of-concept to late-stage trials. Completed in 2023, hVIVO conducted a randomized, double-blind influenza human challenge study in healthy volunteers, providing early proof-of-concept data for CD388 ahead of later stage trials. 59 study participants were enrolled into the study and the primary efficacy analysis comparing the total viral load (area under the curve /AUC) showed a reduction in the CD388 treated arm compared to placebo. Similarly, the peak viral loads measured by both qPCR and cell culture were lowered in CD388 treated participants compared to placebo. This achievement demonstrated hVIVO's ability to execute large-scale field studies with speed and precision. The Phase IIb data read-out showed that all the primary and secondary endpoints were met. The Company continues to support Cidara through Phase III development, acting as a major clinical site for the ongoing multi-site trial. In addition, hVIVO has acted as the central Virology Laboratory for both of Cidara's CD388 Phase IIb and Phase III programs. As part of this service provision hVIVO has provided scientific consultancy, assembled sample collection kits, managed global virology sample logistics, and is responsible for multiple virology and immunology assays including the primary endpoint analysis.
お知らせ • Nov 11hVIVO plc Presents Positive Data from Multiple Novel Human Challenge ModelshVIVO plc announced key insights from its scientific presentations at the 10th European Scientific Working Group on Influenza ("ESWI") Conference in Valencia, and the World Vaccine Congress Europe in Amsterdam, which both took place in October 2025. hVIVO presented positive data from a number of newly developed human challenge models, all demonstrating an acceptable safety and tolerability profile, reinforcing hVIVO's continued capabilities in accelerating the development of novel challenge agents and its readiness to meet customer demand for innovative and effective clinical trial solutions. Human Metapneumovirus ("hMPV") challenge model hVIVO's Senior Study Physician, Dr Alexander Lima, presented the positive findings from the newly developed, and world's only contemporary-strain hMPV human challenge model. The presentation at ESWI, titled, " Disease characteristics and immunological profiles obtained from newly developed hVIVO human challenge model", highlighted the model's strong performance using a recent 2a strain, which compared favourably against hVIVO's established RSV A model, a benchmark for model performance for this particular virus family. The model demonstrated high infection and symptomatic disease attack rates and robust AUC virology by qRT-PCR, and is now ready and available for vaccine and antiviral human challenge trials. SARS-CoV-2 Omicron challenge model Alex Mann, Senior Director Clinical Science presented, " Development of a SARS-CoV- 2 Omicron BA5 human challenge mode l" at ESWI. A key insight from the presentation was the importance of timing of dosing post-inoculation, particularly in the context of post-exposure prophylaxis. This represents the first commercially available Omicron human challenge model. Respiratory Syncytial Virus B (RSV B) challenge model At the World Vaccine Congress Europe, hVIVO's Chief Scientific Officer, Dr Andrew Catchpole showcased the positive results from hVIVO's new RSV B model titled, " High infection rates achieved with the world' first RSV B challenge models key component of the RSV-hMPV-PIV combination vaccine efficacy testing platform. The data confirmed the robustness of the RSV B model, which is now available for vaccine and anti-viral efficacy testing. The development of the RSV B and hMPV models, along with the Company's collecting of PIV (parainfluenza virus) clinical samples, has enabled the Company to create a comprehensive efficacy testing platform enabling the Company to test individual components of the next generation combination vaccines under development.
お知らせ • Sep 04hVIVO plc to Report Q2, 2025 Results on Sep 23, 2025hVIVO plc announced that they will report Q2, 2025 results on Sep 23, 2025
お知らせ • Sep 01Hvivo plc Appoints Shaun Chilton to Board of Directors as Non-Executive Chair with Effect from September 1, 2025hVIVO plc Shaun Chilton has joined the Board of Directors as Non-Executive Chair with immediate effect. Shaun brings substantial sector-relevant experience and expertise to the Board, underpinned by a track record of delivering strong growth in sales and enterprise value. He brings over 30 years of experience leading and managing both private and public businesses. Shaun was previously Chief Executive Officer of Clinigen Group plc, a global pharmaceutical services group operating in more than 100 countries and has considerable board experience within UK public companies. He is currently Non-Executive Chair of Avacta Group plc, Non-Executive Chair of Kintiga Limited, and Independent Supervisory Board Member of Product Life Group. The following additional information is provided with regards to the appointment of Shaun Edward Chilton, aged57, in accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies: Current directorships/partnerships: Avacta Group plc; Bellbrook Consulting Limited; Mustang Bidco Limited; Mustang Midco Limited; Mustang Topco Limited. Former directorships/partnerships (within the last five years): C7 Health Limited; Clinigen Clinical Trials Limited; Clinigen Consulting Limited; Clinigen CTS Limited; Clinigen Gap Limited; Clinigen Healthcare Limited; Clinigen Holdings Limited; Clinigen International Holdings Limited; Clinigen Limited; Clinigen Pharma Limited; Definigen Limited; IDIS GA Limited; IDIS Group Holdings Limited; IDIS Group LimitedIDIS Limited; IDIS MA Limited; IDIS Pharma Limited; Iovance Biotherapeutics UK SP Ltd; Keats Healthcare Limited.
お知らせ • Apr 17+ 1 more updatehVIVO plc, Annual General Meeting, May 13, 2026hVIVO plc, Annual General Meeting, May 13, 2026. Location: the offices of dac beachcroft llp, 25 walbrook, ec4n 8af, london United Kingdom
お知らせ • Apr 07hVIVO plc to Report Fiscal Year 2025 Final Results on Apr 15, 2026hVIVO plc announced that they will report fiscal year 2025 final results at 8:00 AM, GMT Standard Time on Apr 15, 2026
お知らせ • Nov 27hVIVO plc Announces Positive Results from Phase IIb TrialhVIVO plc congratulates its client Cidara Therapeutics Inc. which has entered into a definitive agreement under which Merck Sharp & Dohme LLC ("MSD"), through a subsidiary, will acquire Cidara for a total transaction value of approximately $9.2 billion. This transaction underscores the value of hVIVO's unique capabilities in accelerating drug development and validates the Company's strategic role in supporting breakthrough therapies. Cidara's lead candidate, CD388 is an investigational, long-acting, strain-agnostic antiviral agent designed to prevent influenza infection in individuals at higher risk of complications and offers protection against both influenza A and B. CD388 is currently in Phase III clinical development and has received Breakthrough Therapy Designation and Fast Track Designation from the U.S. FDA. hVIVO has partnered with Cidara throughout the development of CD388, delivering critical data that enabled its progression from early proof-of-concept to late-stage trials. Completed in 2023, hVIVO conducted a randomized, double-blind influenza human challenge study in healthy volunteers, providing early proof-of-concept data for CD388 ahead of later stage trials. 59 study participants were enrolled into the study and the primary efficacy analysis comparing the total viral load (area under the curve /AUC) showed a reduction in the CD388 treated arm compared to placebo. Similarly, the peak viral loads measured by both qPCR and cell culture were lowered in CD388 treated participants compared to placebo. This achievement demonstrated hVIVO's ability to execute large-scale field studies with speed and precision. The Phase IIb data read-out showed that all the primary and secondary endpoints were met. The Company continues to support Cidara through Phase III development, acting as a major clinical site for the ongoing multi-site trial. In addition, hVIVO has acted as the central Virology Laboratory for both of Cidara's CD388 Phase IIb and Phase III programs. As part of this service provision hVIVO has provided scientific consultancy, assembled sample collection kits, managed global virology sample logistics, and is responsible for multiple virology and immunology assays including the primary endpoint analysis.
お知らせ • Nov 11hVIVO plc Presents Positive Data from Multiple Novel Human Challenge ModelshVIVO plc announced key insights from its scientific presentations at the 10th European Scientific Working Group on Influenza ("ESWI") Conference in Valencia, and the World Vaccine Congress Europe in Amsterdam, which both took place in October 2025. hVIVO presented positive data from a number of newly developed human challenge models, all demonstrating an acceptable safety and tolerability profile, reinforcing hVIVO's continued capabilities in accelerating the development of novel challenge agents and its readiness to meet customer demand for innovative and effective clinical trial solutions. Human Metapneumovirus ("hMPV") challenge model hVIVO's Senior Study Physician, Dr Alexander Lima, presented the positive findings from the newly developed, and world's only contemporary-strain hMPV human challenge model. The presentation at ESWI, titled, " Disease characteristics and immunological profiles obtained from newly developed hVIVO human challenge model", highlighted the model's strong performance using a recent 2a strain, which compared favourably against hVIVO's established RSV A model, a benchmark for model performance for this particular virus family. The model demonstrated high infection and symptomatic disease attack rates and robust AUC virology by qRT-PCR, and is now ready and available for vaccine and antiviral human challenge trials. SARS-CoV-2 Omicron challenge model Alex Mann, Senior Director Clinical Science presented, " Development of a SARS-CoV- 2 Omicron BA5 human challenge mode l" at ESWI. A key insight from the presentation was the importance of timing of dosing post-inoculation, particularly in the context of post-exposure prophylaxis. This represents the first commercially available Omicron human challenge model. Respiratory Syncytial Virus B (RSV B) challenge model At the World Vaccine Congress Europe, hVIVO's Chief Scientific Officer, Dr Andrew Catchpole showcased the positive results from hVIVO's new RSV B model titled, " High infection rates achieved with the world' first RSV B challenge models key component of the RSV-hMPV-PIV combination vaccine efficacy testing platform. The data confirmed the robustness of the RSV B model, which is now available for vaccine and anti-viral efficacy testing. The development of the RSV B and hMPV models, along with the Company's collecting of PIV (parainfluenza virus) clinical samples, has enabled the Company to create a comprehensive efficacy testing platform enabling the Company to test individual components of the next generation combination vaccines under development.
お知らせ • Sep 04hVIVO plc to Report Q2, 2025 Results on Sep 23, 2025hVIVO plc announced that they will report Q2, 2025 results on Sep 23, 2025
お知らせ • Sep 01Hvivo plc Appoints Shaun Chilton to Board of Directors as Non-Executive Chair with Effect from September 1, 2025hVIVO plc Shaun Chilton has joined the Board of Directors as Non-Executive Chair with immediate effect. Shaun brings substantial sector-relevant experience and expertise to the Board, underpinned by a track record of delivering strong growth in sales and enterprise value. He brings over 30 years of experience leading and managing both private and public businesses. Shaun was previously Chief Executive Officer of Clinigen Group plc, a global pharmaceutical services group operating in more than 100 countries and has considerable board experience within UK public companies. He is currently Non-Executive Chair of Avacta Group plc, Non-Executive Chair of Kintiga Limited, and Independent Supervisory Board Member of Product Life Group. The following additional information is provided with regards to the appointment of Shaun Edward Chilton, aged57, in accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies: Current directorships/partnerships: Avacta Group plc; Bellbrook Consulting Limited; Mustang Bidco Limited; Mustang Midco Limited; Mustang Topco Limited. Former directorships/partnerships (within the last five years): C7 Health Limited; Clinigen Clinical Trials Limited; Clinigen Consulting Limited; Clinigen CTS Limited; Clinigen Gap Limited; Clinigen Healthcare Limited; Clinigen Holdings Limited; Clinigen International Holdings Limited; Clinigen Limited; Clinigen Pharma Limited; Definigen Limited; IDIS GA Limited; IDIS Group Holdings Limited; IDIS Group LimitedIDIS Limited; IDIS MA Limited; IDIS Pharma Limited; Iovance Biotherapeutics UK SP Ltd; Keats Healthcare Limited.
お知らせ • Jul 18hVIVO plc Announces Resignation of Tracey James as Non-Executive Director, Effective 18 July 2025hVIVO plc announced that the Company has received notice of resignation from Tracey James as Non-Executive Director of the Board with immediate effect (18 July 2025). The Company confirmed that Ms. James' decision to resign from the Board is unrelated to the Company's financial performance or outlook. The Nominations Committee has commenced a process to appoint a new independent Non-Executive Director, and the Company will announce the results of this process in due course. Separately, the Nominations Committee is progressing well in its process to appoint a new independent Non-Executive Chair, with a further announcement to be made in due course.
お知らせ • May 13hVIVO plc, Annual General Meeting, Jun 05, 2025hVIVO plc, Annual General Meeting, Jun 05, 2025. Location: the offices of cavendish capital markets ltd, 1 bartholomew close, ec1a 7bl, london United Kingdom
お知らせ • Apr 10+ 1 more updatehVIVO plc Proposes Ordinary Dividend for the Year Ended 31 December 2024, Payable 11 June 2025hVIVO plc announced A final dividend for the year ended 31 December 2024 of £1,374,000 (0.20p per ordinary share) is recommended by the Directors and is to be paid to all ordinary shareholders on the register at the close of business on 16 May 2025 with payment being made on 11 June 2025, subject to shareholder approval at the Annual General Meeting. The corresponding ex-dividend date is 15 May 2025.
お知らせ • Mar 21hVIVO plc to Report Fiscal Year 2024 Results on Apr 10, 2025hVIVO plc announced that they will report fiscal year 2024 results at 11:00 AM, GMT Standard Time on Apr 10, 2025
お知らせ • Feb 27hVIVO plc (AIM:HVO) acquired Cryo Store Limited.hVIVO plc (AIM:HVO) acquired Cryo Store Limited on February 27, 2025. Under the terms of the Acquisition, three managers of Cryostore will be issued up to 2,773,982 ordinary shares of £1p each in hVIVO ('Consideration Shares') with an aggregate value of up to £0.5 million at the average closing share price for the ten days prior to 24 February 2024. 1,386,991of the Consideration Shares (being 50%) will be allotted on the 12-month anniversary of completion with1,386,991 of the Consideration Shares (being 50%) being allotted on the second anniversary of the Acquisition, subject to the individuals remaining in service of the Group at the time of the allotments. For the period ending December 31, 2024, Cryo Store Limited reported total revenue of £0.89 million and EBITDA of £0.52 million. As of December 31, 2024, Cryo Store Limited reported total common equity of £0.84 million. Geoff Nash, Camilla Hume, Harriet Ward, Nigel Birks, Louise Talbot of Cavendish Capital Markets Limited acted as financial advisor for hVIVO plc. hVIVO plc (AIM:HVO) completed the acquisition of Cryo Store Limited on February 27, 2025.
お知らせ • Jan 31hVIVO plc (AIM:HVO) acquired Two Clinical Research Units of Crs Clinical Research Services Management GmbH for €10 million.hVIVO plc (AIM:HVO) acquired Two Clinical Research Units of Crs Clinical Research Services Management GmbH for €10 million on January 29, 2025. Under the terms of agreement, the Acquisition has been completed for a cash consideration of €10.0 million, wholly funded from the Group's existing cash resources. For the period ending December 31, 2024, The Mannheim and Kiel units recorded unaudited revenues of €19.9 million, with an adjusted EBITDA loss of €1.8 million. Under hVIVO's ownership the two units will undergo an investment and restructuring programme to assist with their integration which is expected to cost c.€2.5 million in 2025 including net liabilities being acquired of less than €0.5 million. Following the Acquisition, average contract sizes across the Group are anticipated to increase, as well as growth in the CRS sales pipeline. The current senior leadership team at CRS, consisting of Dr. Elisabeth Lackner, Chief Executive Officer; Catherine Canales, Chief Commercial Officer; Prof. Dr. Thomas Forst, Chief Medical Officer; and Till Mieskes, Chief Financial Officer, will continue in their roles. The Acquisition expected to be earnings accretive in 2026. The integration of the Acquisition into the wider Group is expected to impact EBITDA margins in the short term and the Group expects to deliver strong revenue growth in 2026 and a significant improvement on EBITDA margins following the integration of CRS. Geoff Nash and Camilla Hume of Cavendish Capital Markets Limited acted as financial advisor for hVIVO plc. hVIVO plc (AIM:HVO) completed the acquisition of Two Clinical Research Units of Crs Clinical Research Services Management GmbH on January 29, 2025.
お知らせ • Aug 20hVIVO plc to Report First Half, 2024 Results on Sep 10, 2024hVIVO plc announced that they will report first half, 2024 results on Sep 10, 2024
お知らせ • Aug 05hVIVO Proposes Cancellation of Admission to Trading on Euronext GrowthhVIVO plc announced its intention to cancel its admission ("the Cancellation") to trading on Euronext Growth. As hVIVO's primary operations, along with the majority of its employees and investor base, are in the UK,the Board has decided to consolidate trading of the Company's stock to its primary listing on the AIM Market of the London Stock Exchange. The Cancellation will also remove certain costs, complexities and duplication that comes from administering two listing regimes and will have no impact on hVIVO's Ordinary Shares which will continue to trade on AIM under the ticker "HVO". In accordance with the Euronext Growth Rules, the Company has notified Euronext of the proposed Cancellation. Under the Euronext Growth Rules, the Cancellation can only take place after the expiry of a minimum period of twenty Business Days from the date on which notice of the Cancellation is given. Accordingly, it is intended that the Cancellation will become effective at 7.00 a.m. on 2 September 2024.
お知らせ • Apr 16hVIVO plc, Annual General Meeting, May 13, 2024hVIVO plc, Annual General Meeting, May 13, 2024, at 10:00 Coordinated Universal Time.
New Risk • Apr 09New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 17% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings are forecast to decline by an average of 17% per year for the foreseeable future.
Reported Earnings • Apr 09Full year 2023 earnings released: EPS: UK£0.024 (vs UK£0.001 loss in FY 2022)Full year 2023 results: EPS: UK£0.024 (up from UK£0.001 loss in FY 2022). Revenue: UK£58.7m (up 16% from FY 2022). Net income: UK£16.1m (up UK£16.9m from FY 2022). Profit margin: 28% (up from net loss in FY 2022). The move to profitability was primarily driven by lower expenses. Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 142% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
お知らせ • Mar 27hVIVO plc to Report Fiscal Year 2023 Results on Apr 09, 2024hVIVO plc announced that they will report fiscal year 2023 results on Apr 09, 2024
お知らせ • Feb 15hVIVO plc has completed a Follow-on Equity Offering in the amount of £8.38745 million.hVIVO plc has completed a Follow-on Equity Offering in the amount of £8.38745 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 29,955,178 Price\Range: £0.28 Transaction Features: Subsequent Direct Listing
Buying Opportunity • Jan 05Now 22% undervaluedOver the last 90 days, the stock is up 32%. The fair value is estimated to be €0.37, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 39% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 6.5% per annum. Earnings is also forecast to grow by 17% per annum over the same time period.
お知らせ • Jan 02hVIVO plc Signs £6.3 Million Human Challenge Study ModelhVIVO plc announced that it has signed a £6.3m contract with a biotechnology client to test its antiviral candidate using the hVIVO Human Rhinovirus (HRV - common cold virus) Human Challenge Study Model. The Phase 2a randomised, double-blinded placebo-controlled human challenge trial is planned to take place at the Company's new specialist quarantine facilities in Canary Wharf. It will evaluate the effect of the antiviral candidate on viral load, safety, tolerability, and prophylactic antiviral activity against HRV infection in multiple cohorts of healthy volunteers. The study is expected to commence in H2 2024, with revenue recognised in 2024 and 2025. As part of the study, hVIVO will recruit healthy volunteers via the Company's dedicated volunteer recruitment arm, FluCamp. This biotechnology client recognises the benefit of human challenge in quickly generating early human efficacy data, which has the potential of significantly enhancing the value of their clinical asset. Human rhinoviruses (HRV) are a group of pathogens that cause 'the common cold', with over 150 distinct types of HRV currently known. Although one third of HRV infections are asymptomatic, it can be potentially serious in the elderly, immunocompromised and those with existing respiratory diseases, and there is strong evidence of a relationship between HRV infection and more severe symptoms of asthma and COPD. To date, no antiviral has been approved in the prevention or treatment of HRV infection.
お知らせ • Sep 12hVIVO plc Increases Revenue Guidance for 2023The Board of hVIVO plc has increased its revenue guidance to £55 million for 2023.
お知らせ • Aug 24hVIVO plc to Report First Half, 2023 Results on Sep 12, 2023hVIVO plc announced that they will report first half, 2023 results on Sep 12, 2023
お知らせ • Jun 30hVIVO plc to Develop Human Metapneumovirus Challenge ModelhVIVO plc is developing a human metapneumovirus (hMPV) challenge model. hVIVO has signed an agreement with a North American biopharmaceutical company to manufacture a hMPV virus and conduct a characterisation study, with the intent to conduct a subsequent hMPV challenge trial in 2024 to test the efficacy of its vaccine candidate. hVIVO will commence Good Manufacturing Practice (GMP) compliant virus manufacturing activities immediately and this is expected to complete in first half 2024. The Company will then conduct a characterisation study to identify a safe and infectious dose of wild-type hMPV in up to 36 healthy adult volunteers. Dependent on the successful completion of the characterisation study and receipt of relevant regulatory approvals, the Company expects to conduct hMPV challenge trials from second half of 2024. The majority of the revenue from this end-to-end human challenge service will be recognised in 2024. The client intends to utilise the efficacy data from the challenge study to define the endpoints for its hMPV vaccine candidate's clinical development programme, as well as providing a greater understanding of virus progression, aiding dosing decisions and confirming previous animal study results. This will allow the client to streamline future trials and make critical go/no-go decisions more quickly, therefore accelerating the development of the vaccine candidate. hMPV is a common virus that causes an upper respiratory infection, similar to the common cold. Symptoms include cough, fever, nasal congestion, and shortness of breath. Most people have mild cases of hMPV, but severe cases can result in bronchiolitis, bronchitis and pneumonia. hMPV is associated with approximately 20% of respiratory tract infections in children worldwide. Up to 16% of the children infected with hMPV develop more severe symptoms2, with over 16,000 deaths worldwide in children under the age of five each year. Despite its prevalence and potential severity, there are currently no vaccines or antivirals approved to treat hMPV.
Reported Earnings • Apr 30Full year 2022 earnings released: UK£0.001 loss per share (vs UK£0 in FY 2021)Full year 2022 results: UK£0.001 loss per share (further deteriorated from UK£0 in FY 2021). Revenue: UK£50.7m (up 30% from FY 2021). Net loss: UK£776.0k (loss widened UK£702.0k from FY 2021). Revenue is forecast to grow 8.3% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 103% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth.
Breakeven Date Change • Apr 27Forecast to breakeven in 2023The 3 analysts covering hVIVO expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of UK£5.19m in 2023. Average annual earnings growth of 53% is required to achieve expected profit on schedule.
お知らせ • Jan 25hVIVO plc Provides Earnings Guidance for the Full Year 2022hVIVO plc provided earnings guidance for the full year 2022. The group expected to report record full year revenues of £50.6 million (2021: £39 million), a 30% increase year-on-year. The significant growth in revenue provides further validation of the long-term sustainable growth in the human challenge trial market, for which hVIVO is the world leader.
Breakeven Date Change • Dec 31Forecast breakeven date pushed back to 2023The 3 analysts covering hVIVO previously expected the company to break even in 2022. New consensus forecast suggests the company will make a profit of UK£4.59m in 2023. Average annual earnings growth of 57% is required to achieve expected profit on schedule.
お知らせ • Dec 20hVIVO plc Announces Publication of Imutex Phase I DatahVIVO plc announces publication of previously reported positive data from a first-in-human Phase I clinical study evaluating the safety and immunogenicity of AGS-v PLUS. The data has been published in eBioMedicine,1 a peer-reviewed open access biomedical journal part of The Lancet Discovery Science. AGS-v PLUS is a vaccine candidate against arboviral diseases that targets the saliva of the mosquito rather than the pathogens carried by the mosquito. AGS-v PLUS is owned by Imutex Ltd, a joint venture with PepTcell Limited (the parent company of ConserV Bioscience Ltd), in which hVIVO has a 49% shareholding. AGS-v PLUS vaccine candidate has a novel proposed dual action mechanism of preventing infection in humans whilst controlling the mosquito population through affecting reproduction. AGS-v PLUS contains five synthetic peptides that originate from proteins found in the saliva of mosquitoes. The published manuscript shows data from the study conducted at the University of Maryland School of Medicine and sponsored by NIAID-NIH, demonstrating that all AGS-v PLUS formulations evaluated (non-adjuvanted or adjuvanted in alhydrogel or Montanide ISA-51) were well tolerated with no serious adverse events experienced, and that they generated a robust cellular and humoral immune response in participants, the formulation in Montanide ISA-51 being the most immunogenic. Moreover, the immune response mounted against AGS-v PLUS was shown to reduce infectivity of Zika virus in vitro. Mosquito-borne diseases include Zika, West Nile, chikungunya, dengue, yellow fever, and malaria amongst others. There are ~360 million cases of and more than 600,000 deaths from mosquito-borne diseases annually, although the true burden is likely underestimated. A vaccine efficacious against multiple mosquito-borne diseases could significantly impact public health.
Buying Opportunity • Dec 20Now 20% undervaluedOver the last 90 days, the stock is up 29%. The fair value is estimated to be €0.15, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 66% over the last 3 years. Earnings per share has grown by 97%.
Board Change • Nov 16Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (4 non-independent directors). Non-Executive Chairman Cathal Friel is the most experienced director on the board, commencing their role in 2020. Independent Non-Executive Director Martin Gouldstone was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Oct 18+ 1 more updateOpen Orphan plc Announces Chief Financial Officer ChangesOpen Orphan plc announced the appointment of Stephen Pinkerton as Chief Financial Officer and as an Executive Director, effective with immediate effect. Stephen will succeed Leo Toole who steps down from the Board and CFO role to pursue other interests. Leo will remain with the Company until 31 December 2022. Stephen is a chartered accountant with over 25 years of experience in senior financial roles and has served as Commercial Financial Director of hVIVO since July 2017, having previously been a consultant to the Company. Prior to joining hVIVO, Stephen spent 11 years in various senior financial roles at Thomson Reuters. He will be based in the Company's Plumbers Row headquarters in East London alongside the Company's CEO Yamin 'Mo' Khan. Stephen has a strong background in financial planning and analysis, commercial finance, financial systems and financial control. As Commercial Financial Director of hVIVO, he has worked to transform the reporting and forecasting of the business, developed pricing models for contracts to help improve average contract value as well as driving margin improvements across the business, and has served as part of the business development team negotiating contract terms. As part of the leadership team, he has worked to help manage costs and restructure the business to improve efficiency, resulting in continued improvements in profitability.
お知らせ • Oct 01Open Orphan plc Announces Positive Data from Peer-Reviewed Study Evaluating the in Vitro Efficacy of Flu-VOpen Orphan plc announced that positive data from a peer-reviewed study evaluating the in vitro efficacy of FLU-v, Imutex Limited's ("Imutex") broad spectrum influenza vaccine, has been published in the scientific journal Vaccines. Previous clinical studies have demonstrated that FLU-v induced increased antibody and cellular responses in vivo. This placebo-controlled study evaluated the ability of FLU-v to induce cellular effector functions and cross-reactivity (both measures of the immune response, with cross-reactivity being particularly important for protection against multiple viral strains) of immune cells extracted from participants, following exposure to five different influenza strains.The study found that measurements ofIFN-? and granzyme B production in stimulated immune cells from participants that had been previously vaccinated with either FLU-v or placebo, were significantly higher in the FLU-v group both when stimulated with vaccine antigen and also with antigens from a panel of seasonal and pandemic inactivated influenza A and B strains. These results further support the continued development of FLU-v as a broad-spectrum influenza vaccine. FLU-v is owned by Imutex, a joint venture between hVIVO andPepTcell Limited (the legal name of SEEK Group), to develop vaccines against influenza and mosquito borne diseases such as Zika virus, malaria and other flaviviruses.
Reported Earnings • Sep 09First half 2022 earnings released: EPS: UK£0 (vs UK£0.002 in 1H 2021)First half 2022 results: EPS: UK£0 (down from UK£0.002 in 1H 2021). Revenue: UK£18.9m (down 14% from 1H 2021). Net income: UK£277.0k (down 78% from 1H 2021). Profit margin: 1.5% (down from 5.8% in 1H 2021). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
お知らせ • Sep 08Open Orphan plc Reiterates Revenue Guidance for the Full Year of 2022Open Orphan Plc reiterated revenue guidance for the full year of 2022. For the year, the company reiterated revenue guidance of c. £50 million, underpinned by robust trading in July and August and record contracted order book increased nearly threefold to c. £70 million as at 30 June 2022.
お知らせ • Aug 25Open Orphan Plc to Report First Half, 2022 Results on Sep 08, 2022Open Orphan Plc announced that they will report first half, 2022 results on Sep 08, 2022
お知らせ • Jun 11Open Orphan plc, Annual General Meeting, Jul 05, 2022Open Orphan plc, Annual General Meeting, Jul 05, 2022, at 10:00 Coordinated Universal Time. Location: at the offices of DAC Beachcroft LLP, 25 Walbrook London United Kingdom
Reported Earnings • Jun 08Full year 2021 earnings released: EPS: UK£0 (vs UK£0.018 loss in FY 2020)Full year 2021 results: EPS: UK£0 (up from UK£0.018 loss in FY 2020). Revenue: UK£39.0m (up 89% from FY 2020). Net loss: UK£74.0k (loss narrowed 99% from FY 2020). Over the next year, revenue is forecast to grow 7.0%, compared to a 13% growth forecast for the pharmaceuticals industry in Germany.
お知らせ • Jun 08Open Orphan plc Appoints Martin Gouldstone as Independent Non-Executive DirectorOpen Orphan plc announced the appointment of Martin Gouldstone as an Independent Non-Executive Director of the Company with effect from 8 June 2022.Martin will also Chair the Audit & Risk Committee and will be a member of the Nominations Committee and the Remuneration Committee. Martin brings 30 years of corporate development experience in the CRO, healthcare and pharmaceutical sectors, holding a number of senior roles at healthcare AI businesses. Martin has expertise in executing multi-billion dollar deals across Europe and the US, architecting end-to-end portfolio out-sourcing deals, and negotiating multi-year research partnerships. Martin is currently Global SVP, Business Development at Owkin. Previously, Martin has held the roles of Chief Business Officer at both BenevolentAI and Sensyne Health and was a Partner at Results Healthcare. Prior to this, Martin was Head of Life Sciences for BDO UK LLP, Senior Director responsible for M&A and joint venture opportunities in Europe for Quintiles (now IQVIA), and Business Development and Licensing Lead at Confirmant Ltd, Pharmacopeia Inc, Sareum Ltd. Martin holds a BSc in Genetics and has completed a range of post graduate management courses.
お知らせ • May 24Open Orphan plc to Report Fiscal Year 2021 Results on Jun 07, 2022Open Orphan plc announced that they will report fiscal year 2021 results on Jun 07, 2022
Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 1 independent director (4 non-independent directors). Executive Chairman Cathal Friel is the most experienced director on the board, commencing their role in 2020. Independent Non-Executive Director Elaine Sullivan was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Apr 01Open Orphan plc Announces Characterisation Study Results in Nature MedicineOpen Orphan plc announced that the results from the world's first COVID-19 characterisation study have been peer reviewed and published in the scientific journal Nature Medicine. The study, which was conducted by hVIVO, a subsidiary of Open Orphan, in partnership with Imperial College London, the Vaccine Taskforce and Department of Health and Social Care (DHSC), and the Royal Free London NHS Foundation Trust, showed that the SARS-CoV-2 human challenge was safe in healthy young adults and provided detailed insights into the course of COVID-19 infection with potential positive public health implications. The study results had previously been published on Research Square whilst the peer review process was concluding. As part of the characterisation study, researchers aimed to identify a dose of COVID-19 that caused a safe and reliable infection in unvaccinated volunteers with no prior SARS-CoV-2 infection. hVIVO clinicians closely monitored volunteers in a controlled quarantined setting and collected disease progression data to provide insights into COVID-19 infection. With the characterisation study disease modelling data completed, and a COVID-19 Human Challenge Model now established, Open Orphan should be able to contract /conduct COVID-19 human challenge studies in 2022, subject to individual ethics and regulatory approvals.
お知らせ • Feb 24Open Orphan plc Appoints Yamin 'Mo' Khan as Chief Executive OfficerOpen Orphan plc announces the appointment of Yamin 'Mo' Khan as Chief Executive Officer of Open Orphan with immediate effect. He previously worked at Pharm-Olam International, a global CRO, for 19 years from 2000-2019.
Reported Earnings • Sep 22First half 2021 earnings released: EPS UK£0.002 (vs UK£0.012 loss in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: UK£21.9m (up 242% from 1H 2020). Net income: UK£1.27m (up UK£7.76m from 1H 2020). Profit margin: 5.8% (up from net loss in 1H 2020). The move to profitability was driven by higher revenue.
Recent Insider Transactions • Jul 16Executive Chairman recently bought €352k worth of stockOn the 14th of July, Cathal Friel bought around 1m shares on-market at roughly €0.31 per share. This was the largest purchase by an insider in the last 3 months. This was Cathal's only on-market trade for the last 12 months.
Reported Earnings • Jun 20Full year 2020 earnings released: UK£0.018 loss per share (vs UK£0.034 loss in FY 2019)The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2020 results: Revenue: UK£20.6m (up UK£17.3m from FY 2019). Net loss: UK£10.8m (loss widened 95% from FY 2019).
Is New 90 Day High Low • Feb 23New 90-day high: €0.35The company is up 34% from its price of €0.26 on 24 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.083 per share.
お知らせ • Feb 18Open Orphan plc Announces Ethics Approval for Covid-19 Human Challenge StudyOpen Orphan plc announced the COVID-19 characterisation study has received approval from a specially convened Research Ethics Committee ("REC"). The initial virus characterisation study will inoculate up to 90 volunteers, between the ages of 18 and 30 years old, to enable identification of the most appropriate dose of the virus needed to cause COVID-19 (SARS-CoV-2) infection in a safe and controlled environment. The study is set to commence shortly and is funded by the UK Government. Imperial College London is the clinical study sponsor and the study will be conducted by hVIVO at the Royal Free London NHS Foundation Trust's specialist clinical research unit, under the scrutiny of highly trained scientists and medics. The virus being used in the characterisation study has been produced under hVIVO's supervision by a team at Great Ormond Street Hospital for Children NHS Foundation Trust in London, with support from virologists at Imperial College London. The REC approval completes all the independent external body approvals required before the study can commence.
お知らせ • Feb 02Open Orphan Plc's Subsidiary Venn Life Sciences Announces Contract Extension with Carna BiosciencesOpen Orphan plc announced a further contract renewal with Carna Biosciences Inc., extending its integrated drug development consultancy services with Venn Life Sciences, part of Open Orphan plc. The Venn team in the Breda office in the Netherlands, will provide Chemistry, Manufacturing & Control (CMC), Non-Clinical, Clinical and Regulatory consultancy services to this client for two of the client's leading development programmes. This successful collaboration has been extended until the end of December 2021.
Is New 90 Day High Low • Jan 27New 90-day high: €0.33The company is up 44% from its price of €0.23 on 29 October 2020. The German market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.099 per share.
お知らせ • Jan 07Open Orphan plc Announces Contract Renewal with Top-3 Pharmaceutical Client Extending Its Consultancy Services to End of December 2021Open Orphan plc announced a further contract renewal with a major top-3 global pharmaceutical client extending its consultancy services to end of December 2021. This follows on from the announcement made on 22 December 2020 regarding the same client and demonstrates the repeat business that Venn Life Sciences continues to win from its long-term clients. The Venn team in the Breda office in the Netherlands, will provide Chemistry, Manufacturing & Control consultancy services to this leading global pharmaceutical client for one of the client's vaccine development programmes and follows the recently announced contract renewal for work on two of the client's vaccine development programmes. This successful collaboration has been extended until end of December 2021.
お知らせ • Nov 25Open Orphan plc Announces Board Changes, Effective on December 31, 2020Open Orphan plc announced the appointment of Elaine Sullivan as a Non-Executive Director to the board of the company. Elaine is a business leader and senior scientist with international experience in the pharmaceutical industry and Biotech and is the CEO of Curadh Pharmaceuticals. She has been a member of the most senior R&D management teams in Lilly and AstraZeneca. Elaine is a Non-Executive Director at IP Group plc and Active Biotech AB and is a member of the Supervisory Board at Evotec. The company also announced that Mark Warne, Non-Executive Director, will be stepping down from the board of the company on the of December 31.
お知らせ • Nov 06Open Orphan plc Announces the Signs of A £2.5 Million Contract by hVIVOOpen Orphan plc announced the signing of a £2.5 million contract by hVIVO, a subsidiary of Open Orphan, to conduct an Influenza human challenge study with a US biotechnology company. The study is expected to commence at hVIVO's 24-bedroom quarantine clinic in East London in H2 2021 and to be fully completed by year end 2021, generating £2.5m of revenue. This contract builds on the Company's recent challenge study contract wins in RSV and COVID-19 and demonstrates the breadth of Open Orphan's service offering and the expertise within the Group as a world leader in its field. For this study, Venn Life Science's Paris team will complete the biometrics, demonstrating how the various parts of the Open Orphan plc Group can work together to deliver high-quality services to clients. Venn's Paris team are highly regarded in the field as one of the leading providers in this area which is a perfect complement to the London offering.
Is New 90 Day High Low • Oct 05New 90-day high: €0.21The company is up 87% from its price of €0.11 on 07 July 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 18% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.29 per share.
Is New 90 Day High Low • Oct 01New 90-day high: €0.20The company is up 66% from its price of €0.12 on 03 July 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 19% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.32 per share.
お知らせ • Oct 01Open Orphan plc Announces £4.3 Million Contract to Conduct Human Viral Challenge StudyOpen Orphan plc announced £4.3 million contract to conduct human viral challenge study utilizing one of 8 traditional challenge study models for another of the global top 10 vaccine companies. This trial will be conducted in the company's dedicated human viral challenge quarantine unit in London with all volunteers recruited through hVIVO's volunteer recruitment website, www.flucamp.com. The hVIVO unit is Europe's only commercial 24-bedroom quarantine clinic with on-site virology laboratory. Work on this major new contract has started already and the contract is expected to be delivered in first quarter of 2021 with the majority of revenues being generated in first half of 2021. It is a further example of Open Orphan delivering on its pipeline and stated strategy of winning sizeable contracts.
お知らせ • Sep 28Open Orphan plc to Report First Half, 2020 Results on Sep 30, 2020Open Orphan plc announced that they will report first half, 2020 results on Sep 30, 2020
